Abstracts tagged "Uric Acid, Urate"

Abstract Number: 1105 • ACR Convergence 2023
Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients
Jinseok kim, Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea
Background/Purpose: Many studies have reported that gout and hyperuricemia are associated with an increase in all-cause mortality and cardiovascular mortality.Increased vascular stiffness is closely related…
Abstract Number: 1107 • ACR Convergence 2023
Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy
James Mossell¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux² and Sanjay Chabra³, ¹Arthritis and Osteoporosis Center of South Georgia, Tifton, GA, ²Horizon Therapeutics, Deerfield, IL, ³Texas Arthritis Center, El Paso, TX
Background/Purpose: Pegloticase can lower serum urate (SU) in patients with uncontrolled gout who are refractory to/intolerant of oral urate-lowering therapies. However, antidrug antibodies (ADAs) can…
Abstract Number: 0038 • ACR Convergence 2023
Specific Binding of Uric Acid to NDFIP1 Associates with Hyperuricemia-induced Ferroptosis
Qiunan Zhu¹, Hiroshi Arakawa², Yoshiyuki Shirasaka² and Ikumi Tamai², ¹Kanazawa University, Kanazawa, Japan, ²Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan
Background/Purpose: Hyperuricemia (HU) is reported as a risk factor for gout and associates with diverse diseases, including ulcerative colitis (UC), while its mechanism remains unclear.…
Abstract Number: 1110 • ACR Convergence 2023
Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Roy Fleischmann¹, James Cheng-Chung Wei², Zancong Shen³, sarah Morris⁴, Elizabeth Polvent⁵, Andrea Clouser-Roche⁴, Vijay Hingorani⁶, Rongzi Yan⁷, Shunqi Yan⁸, Robert Keenan⁹ and Li-Tain Yeh¹⁰, ¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ³Arthrosi Therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc, Irvine, CA, ⁸Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC, ¹⁰Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…
Abstract Number: 1111 • ACR Convergence 2023
Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis
Palapun Waitayangkoon¹, Tatchaya Kanthajan² and Thiratest Leesutipornchai³, ¹MetroWest Medical Center, Framingham, MA, ²Srinakharinwirot University, Bangkok, Thailand, ³University of Hawaii, Honolulu, HI
Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide…
Abstract Number: 0234 • ACR Convergence 2023
Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
Sara Tedeschi¹, Keigo Hayashi¹, Yuqing Zhang², Hyon K. Choi³ and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: ACR gout treatment guidelines recommend a target serum urate (SU) of < 6 mg/dL and anti-inflammatory flare prophylaxis for at least 3-6 months after…
Abstract Number: 1112 • ACR Convergence 2023
AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Zancong Shen¹, Elizabeth Polvent², sarah Morris³, Rongzi Yan⁴, Shunqi Yan⁵, Robert Keenan⁶ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Chapel Hill, NC, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: The uric acid transporter inhibitor (URAT1) is responsible for the reabsorption of filtered uric acid from the renal tubular lumen. Uricosuric agents inhibit URAT1…
Abstract Number: 0237 • ACR Convergence 2023
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
Lissa Padnick-Silver¹, Andrew Concoff², Hong-Ye Gao¹, Qianhong Fu¹, Brian LaMoreaux¹ and N. Lawrence Edwards³, ¹Horizon Therapeutics, Deerfield, IL, ²United Rheumatology, Happauge, NY, ³University of Florida College of Medicine, Gainesville, FL
Background/Purpose: Pegloticase, a recombinant pegylated uricase, rapidly reduces serum urate (SU) in patients refractory to/intolerant of oral urate-lowering therapies (ULTs).1,2 However, pegloticase is generally used…
Abstract Number: 1145 • ACR Convergence 2023
Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat
Ryan Feaver¹, Scott Bowers², Banumathi Cole¹, Steve Hoang¹, Mark Lawson¹, Justin Taylor¹, Brian LaMoreaux², Lin Zhao², Brad R Henke¹, Brian Johns¹, Andrew C Nyborg², Brian R Wamhoff¹ and Rob Figler¹, ¹HemoShear Therapeutics, Charlottesville, VA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Gout is a chronic inflammatory arthritis that is undertreated and managed with the xanthine oxidase inhibitors febuxostat or allopurinol. Despite the United States Food…
Abstract Number: 1678 • ACR Convergence 2022
A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout
Tony Merriman¹, Hirotaka Matsuo², Riku Takei³, Megan Leask³, Ruth Topless¹, Yuya Shirai⁴, Zhiqiang Li⁵, Murray Cadzow¹, Richard Reynolds³, kenneth saag³, Tayaza Fadason⁶, Justin O'Sullivan⁶, Nicola Dalbeth⁶, Lisa Stamp⁷, Abhishek Abhishek⁸, Michael Doherty⁸, Edward Roddy⁹, Lennart Jacobsson¹⁰, Meliha Kapetanovic¹¹, Mariano Andrès¹², Fernando Perez-Ruiz¹³, Rosa Torres Jimenez¹⁴, Timothy Radstake¹⁵, Timothy Jansen¹⁶, Matthijs Janssen¹⁷, Leo Joosten¹⁸, Tania Octavia Crisan¹⁹, Tom Huizinga²⁰, Frederic LIOTE²¹, Pascal Richette²², Thomas Bardin²³, Tristan Pascart²⁴, Geraldine McCarthy²⁵, Blanka Stiburkova²⁶, Anne Tausche²⁷, Till Uhlig²⁸, Veronique Vitart²⁹, Philip Riches²⁹, Stuart Ralston²⁹, Thomas MacDonald³⁰, Akiyoshi Nakayama², Masahiro Nakatochi³¹, Kimiyoshi Ichida³², Tappei Takada³³, Chaeyoung Lee³⁴, Matthew Brown³⁵, Philip Robinson³⁶, Catherine Hill³⁷, Hyon Choi³⁸, Nicholas Sumpter³, Marilyn Merriman³, Amanda Phipps-Green¹, Wenhua Wei¹, Sally McCormick¹, Olle Melander³⁹, René Toes²⁰, Hang-Korng Ea²¹, Fina Kurreeman²⁰, Laura Helbert²⁵, Thibaud Boutin²⁹, Nariyoshi Shinomiya², Linda Bradbury⁴⁰, Russell Buchanan⁴¹, Susan Lester³⁷, Malcolm Smith⁴², Maureen Rischmueller⁴³, On behalf of Japan Gout Genomics Consortium (J-Gout)⁴⁴, On behalf of Japan Multi-Instl Collab Cohort Study (J-MICC)⁴⁵, Eli Stahl⁴⁶, Jeff Miner⁴⁷, Daniel Solomon⁴⁸, Jing Cui⁴⁸, Kathleen Giacomini⁴⁹, Deanna Brackman⁴⁹, Eric Jorgenson⁵⁰, On behalf of 23andMe Research Team⁵¹, Suyash Shringapure⁵¹, Alexander So⁵², Yukinori Okada⁴, Changgui Li⁵, Yongyong Shi⁵³ and Tanya Major¹, ¹University of Otago, Dunedin, New Zealand, ²National Defense Medical College, Saitama, Japan, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Osaka University, Suita, Osaka, Japan, ⁵The Affiliated Hospital of Qingdao University, Qingdao, China, ⁶University of Auckland, Auckland, New Zealand, ⁷University of Otago, Christchurch, New Zealand, ⁸University of Nottingham, Nottingham, United Kingdom, ⁹Keele University, Keele, United Kingdom, ¹⁰Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ¹¹Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö, Lund, Sweden, ¹²Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ¹³University of the Basque Country, Barakaldo, Spain, ¹⁴La Paz University Hospital, Madrid, Spain, ¹⁵University Medical College Uthrecht, Utrecht, Netherlands, ¹⁶VieCuri Medical Centre, Venlo, Netherlands, ¹⁷Rijnstate Hospital, Bennekom, Netherlands, ¹⁸Radboudumc, Nijmegen, Netherlands, ¹⁹University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Cluj-Napoca, Romania, ²⁰Leiden University Medical Center, Leiden, Netherlands, ²¹University of Paris, Paris, France, ²²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ²³Hôpital Lariboisiere, Paris, France, ²⁴Lille Catholic University, Lille, France, ²⁵Mater Misericordiae University Hospital, Dublin, Ireland, ²⁶Institute of Rheumatology, Prague, Czech Republic, ²⁷University Clinic 'Carl Gustav Carus' at the Technical University, Dresden, Germany, ²⁸Diakonhjemmet Hospital, Oslo, Norway, ²⁹University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³⁰University of Dundee, Dundee, United Kingdom, ³¹Nagoya University Hospital, Nagoya, Japan, ³²Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, ³³University of Tokyo Hospital, Tokyo, Japan, ³⁴Soongsil University, Seoul, Republic of Korea, ³⁵Genomics England, London, United Kingdom, ³⁶University of Queensland, Brisbane, Australia, ³⁷The Queen Elizabeth Hospital, Adelaide, Australia, ³⁸Massachusetts General Hospital, Lexington, MA, ³⁹Lund University, Malmö, Sweden, ⁴⁰Gold Coast University Hospital, Brisbane, Australia, ⁴¹Austin Health, Heidelberg, Australia, ⁴²Flinders Medical Centre, Adelaide, Australia, ⁴³RheumatologySA, Adelaide, Australia, ⁴⁴Japan Gout Genomics Consortium (J-Gout), Saitama, Japan, ⁴⁵Japan Multi-Institutional Collaborative Cohort Study (J-MICC), Nagoya, Japan, ⁴⁶Regeneron, New York, NY, ⁴⁷ViscientBio, San Diego, CA, ⁴⁸Brigham and Women's Hospital, Boston, MA, ⁴⁹University of California San Francisco, San Francisco, CA, ⁵⁰Kaiser Permanente, San Francisco, CA, ⁵¹23andMe, Inc., Sunnyvale, CA, ⁵²University of Lausanne, Lausanne, Switzerland, ⁵³Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Genome-wide association studies (GWAS) in gout have been relatively small (≤13,179 people with gout) and have provided little insight into the progression from hyperuricemia…
Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Aakriti Arora¹, Lakshmi Jayaram², TEFERA ESHETU³ and FLORINA CONSTANTINESCU³, ¹MedStar Washington Hospital Center, Georgetown University, Washington, DC, ²McGaw Medical Center, Northwestern University, Chicago, IL, ³MedStar Washington Hospital Center, Washington, DC
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…
Abstract Number: 1793 • ACR Convergence 2022
Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center
Namitha Nair, Dipanjan Debnath and FLORINA CONSTANTINESCU, MedStar Washington Hospital Center, Washington, DC
Background/Purpose: The presence of the HLA-B*5801 allele is strongly associated with Allopurinol Hypersensitivity Syndrome (AHS) manifesting as severe cutaneous adverse reactions (SCARs) like Drug rash…
Abstract Number: 1794 • ACR Convergence 2022
Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department
David Lim¹, Manushi Aggarwal¹ and Marven Cabling², ¹Loma Linda University Health, Redlands, CA, ²Loma Linda University, REDLANDS, CA
Background/Purpose: Gout is the most common inflammatory arthritis in adults that results in high disease burden and health care utilization. The objective of the study…
Abstract Number: 1796 • ACR Convergence 2022
Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans
Nicole Leung¹, Michael Toprover¹, Charles Fang², Michael Pillinger³ and Jay Pendse⁴, ¹Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ²Department of Surgery Division of Vascular and Endovascular Surgery, University of Massachusetts Medical School, Worcester, MA, ³NYU Grossman School of Medicine, New York, NY, ⁴Division of Endocrinology, New York University Grossman School of Medicine and Endocrinology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY
Background/Purpose: Peripheral vascular disease (PVD) causes substantial morbidity and mortality. Patients with gout are known to have increased coronary artery disease risk but less is…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].